glp-1 receptor agonist with dpp-4 inhibitor combination not recommended inhibitors for type 2 diabetes management Acute DPP-4 inhibition modulates vascular

The shared biology of GLP-1 therapies therefore masks a deeper divergence

Chin J Pathophysiol 2016;32:1312-6

It also encourages these companies to keep innovating on new, more differentiating drugs that they will be able to sell at higher prices

95% CI, 0.77-0.93) (93) ( Table 2 )

"Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen SmPC"

Meta-analyses of these and other studies have demonstrated: Reductions in total cholesterol typically in the range of 15% from baseline, varying by agent and population Decreases in LDL cholesterol ranging from 17%, generally more modest than dedicated lipid-lowering therapies Reductions in triglycerides of 515%, with greater effects often seen in those with higher baseline levels Variable effects on HDL cholesterol , with small increases (1-2%) or neutral effects reported The magnitude of lipid improvements appears to correlate with the degree of weight loss achieved, suggesting that metabolic benefits may be partially mediated through adiposity reduction